WEED.TO - Canopy Growth Corporation

Toronto - Toronto Delayed Price. Currency in CAD
46.63
+0.94 (+2.06%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close45.69
Open45.69
Bid46.65 x 0
Ask46.64 x 0
Day's Range45.32 - 46.77
52 Week Range32.01 - 76.68
Volume1,032,047
Avg. Volume1,910,692
Market Cap16.128B
Beta (3Y Monthly)5.15
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Cannabis News: Cash Is King
    Motley Fool8 hours ago

    Cannabis News: Cash Is King

    Analysts say investors are underappreciating the balance-sheet strength of Canopy Growth and Cronos Group.

  • Cannabis stocks slammed after FDA warning to Curaleaf for CBD claims
    MarketWatch9 hours ago

    Cannabis stocks slammed after FDA warning to Curaleaf for CBD claims

    Cannabis stocks were mostly lower on Tuesday, led by Curaleaf Holdings after the U.S. Food and Drug Administration sent a warning letter to the company for claiming CBD-based products could treat a range of serious diseases, including Alzheimer’s disease.

  • Here's How Much Legal Marijuana Canada Has Sold Since Legalizing Adult-Use Cannabis
    Motley Fool15 hours ago

    Here's How Much Legal Marijuana Canada Has Sold Since Legalizing Adult-Use Cannabis

    It's probably a smaller amount than you would have expected.

  • Investing.com15 hours ago

    Curaleaf Slumps Midday After Receiving FDA Warning Letter

    Investing.com - Curaleaf slumped in midday trade Tuesday after receiving a warning letter from the Federal Drug Administration over its promotion of unapproved products containing cannabidiol (CBD).

  • Medical Cannabis for Heart and Blood Pressure Patients
    Market Realist15 hours ago

    Medical Cannabis for Heart and Blood Pressure Patients

    Medical cannabis is gaining widespread acceptance due to increased awareness. Several countries are looking into cannabis as an alternative for existing medicine.

  • How Pet Lovers Will Help Fuel CBD Sales to $24 Billion
    Investopedia16 hours ago

    How Pet Lovers Will Help Fuel CBD Sales to $24 Billion

    CBD pet products are expected to make up 7% of the $24 billion in annual sales forecast for CBD goods in four years.

  • Will Aurora, Canopy, Cronos, and Tilray Be Profitable by 2021?
    Motley Fool2 days ago

    Will Aurora, Canopy, Cronos, and Tilray Be Profitable by 2021?

    Rapid sales growth yields no guarantee of profitability in the cannabis space.

  • Jay-Z, Bubba Watson, Martha Stewart Tout Cannabis as Weed Goes Mainstream
    Investopedia2 days ago

    Jay-Z, Bubba Watson, Martha Stewart Tout Cannabis as Weed Goes Mainstream

    The cannabis industry is gaining increasing mainstream traction as more and more celebrities team up with firms to offer their support.

  • Benzinga2 days ago

    Canopy Rivers' PharmHouse Joint Venture Receives Health Canada License

    Canopy Rivers Inc (OTC: CNPOF ), the venture capital arm of Canopy Growth Corp (NYSE: CGC ), announced Monday its PharmHouse Joint venture had obtained a cultivation license from Health Canada. PharmHouse, ...

  • The Most Important Thing to Know About Investing in Marijuana Stocks
    Motley Fool3 days ago

    The Most Important Thing to Know About Investing in Marijuana Stocks

    This high-growth and budding industry comes with one must-know warning.

  • 3 Terrible Reasons to Sell Canopy Growth
    Motley Fool3 days ago

    3 Terrible Reasons to Sell Canopy Growth

    Thinking about selling your Canopy Growth stock? Don't do it over these three reasons.

  • 3 International Companies Whose Products You May Soon Be Using
    Motley Fool5 days ago

    3 International Companies Whose Products You May Soon Be Using

    The world's a pretty big place. Expand your portfolio's horizons with these international businesses.

  • Aurora Cannabis Stock Falls on Bank of America Downgrade
    Market Realist6 days ago

    Aurora Cannabis Stock Falls on Bank of America Downgrade

    On Thursday, Bank of America downgraded Aurora Cannabis stock (ACB) to “neutral” from its previous “buy” rating. Here's why.

  • Curaleaf's Plan To Become No. 1 in Cannabis
    Investopedia6 days ago

    Curaleaf's Plan To Become No. 1 in Cannabis

    Curaleaf's acquisitions are dramatically expanding its footprint to exploit the market's exploding growth.

  • 3 Cannabis Stocks Worth Considering for Your Portfolio
    Motley Fool6 days ago

    3 Cannabis Stocks Worth Considering for Your Portfolio

    MediPharm Labs, Canopy Growth, and OrganiGram get some love from three of our contributors who cover the marijuana space.

  • Why Is the US CBD Market So Attractive?
    Market Realist6 days ago

    Why Is the US CBD Market So Attractive?

    Brightfield Group estimates that the CBD market could hit about $23.7 billion by 2023. However, regulatory hurdles could impact the US market.

  • Cannabis stocks led higher by Curaleaf after company buys Chicago-based multistate operator
    MarketWatch6 days ago

    Cannabis stocks led higher by Curaleaf after company buys Chicago-based multistate operator

    Cannabis stocks were mostly higher Wednesday, with Curaleaf leading the pack after announcing an $875 million stock-and-cash deal that will help it expand into new states, including Illinois.

  • MarketWatch7 days ago

    Ladenburg Thalmann initiates coverage of cannabis sector with buy ratings on Canopy Growth, Aurora

    Ladenburg Thalmann initiated coverage of the cannabis sector on Wednesday, assigning buy ratings to market leader Canopy Growth Corp. and Aurora Cannabis Inc. , and a neutral rating to Tilray Inc. Analyst Glenn Mattson said he favors Canadian companies who are focused on long-term value creation and gaining market share, along with those with clear plans to enter the U.S. market, which is expected to become the world's biggest, if and when federal laws allow it. "In the U.S. we look for companies that are building a presence in states with large populations but a limited licensing outlook," Mattson wrote in a series of notes to clients. The analyst views Canopy as a compelling investment opportunity, and said he expects it to retain its leading position in Canada--and beyond. "We believe that Canopy can replicate that effort in other markets as those markets move toward legalization," Mattson wrote. "Canopy has the most aggressive approach to capturing the U.S. market (estimated to be the world's largest potentially) through its potential acquisition of Acreage Holdings (ACRGF: $14.50, Buy)," he said. Aurora is "one of the most aggressive capacity expansion plays" in the cannabis sector, with its aim to become the low-cost provider of premium product. "While some firms are being cautious about expansion with the possibility that the Canadian market may see oversupply, Aurora is taking the view that the market for cannabis will be global and it can export to areas like Europe if the Canadian market sees saturation," he wrote. Turning to Tilray, Mattson said that company is supplying medical cannabis to patients in 15 countries and praised its brand strategy and clinical trials. But the plan of distribution of its big shareholder Privateer will create an overhang on the stock that Mattson expects will weigh for some time. "It remains to be seen what kind of traction TLRY will have with CBD in the U.S. and until then we don't believe an established organic foods company should trade at the same multiple as a high-growth cannabis company," he wrote. The ETFMG Alternative Harvest ETF has gained 21% in 2019 to date, while the S&P 500 has gained 20%.

  • Motley Fool7 days ago

    Canopy Growth Just Confirmed What We've Long Suspected

    Canopy CFO Mike Lee dishes on growth expectations for fiscal 2020.

  • Cannabis Outlook From OrganiGram’s Earnings Report
    Market Realist8 days ago

    Cannabis Outlook From OrganiGram’s Earnings Report

    On Monday, OrganiGram (OGI) reported its third-quarter earnings. Following the company's earnings, we reported how it performed in the third quarter. To learn more, read OrganiGram’s Third-Quarter Earnings. Interestingly, OrganiGram stressed that the growth would be heavily driven by retail stores opening in Ontario and Quebec. The company stated that legalizing edibles and derivative products […]

  • 7 Reasons Aurora, Canopy, Cronos, and HEXO Are All At or Near 6-Month Lows
    Motley Fool8 days ago

    7 Reasons Aurora, Canopy, Cronos, and HEXO Are All At or Near 6-Month Lows

    The buzz is beginning to wear off for the most popular cannabis stocks.

  • Organigram a Canadian Pot Rarity After Four Profitable Quarters
    Bloomberg8 days ago

    Organigram a Canadian Pot Rarity After Four Profitable Quarters

    (Bloomberg) -- With four quarters of profitability under its belt, Organigram Holdings Inc. is an anomaly in the Canadian cannabis market.Organigram has higher margins than most of its peers and one of the lowest costs per gram in the industry even though it grows indoors, generally considered the most expensive method of production. Chief Executive Officer Greg Engel attributes this to its ability to get higher yields from its pot plants than companies that grow in greenhouses, as well as its automated packaging lines.“We built a facility and designed a facility that was very focused on high-quality product because we felt there was a market opportunity that was sustainable,” Engel said in an interview at Bloomberg’s Toronto office.Organigram’s streak of profitability comes as the industry undergoes a period of significant upheaval. CannTrust Holdings Inc., previously considered one of the more reputable pot companies, plunged 48% last week after Canadian regulators said it grew cannabis in unlicensed areas of its greenhouse, forcing it to halt all sales and shipments of its products.That came less than a week after Canopy Growth Corp. fired co-CEO Bruce Linton amid shrinking margins and a C$323 million net loss in its most recent quarter.Lower ValuationMoncton, New Brunswick-based Organigram, meanwhile, reported its fourth consecutive quarter on Monday of positive adjusted earnings before interest, taxes, depreciation and amortization, or Ebitda. Revenue of C$25 million ($19 million) missed estimates and gross margin fell to 50% from 60% in the previous quarter, but Eight Capital analyst Graeme Kreindler said he views this as an “isolated event” related to a temporary change in cultivation protocols and the timing of shipments to provinces.Organigram said it cost 95 cents to produce a gram of dried flower in its most recent quarter. That was up from 65 cents in the previous quarter but still compares favorably with C$1.42 at Aurora Cannabis Inc. and $1.48 at Tilray Inc.No other large Canadian pot producer has managed to post such a long string of positive Ebitda. However, although it’s one of the best-performing pure-play pot stocks this year, up 64%, its valuation as measured by its price-to-sales ratio is well below those of its largest competitors.Engel is unperturbed. “At the end of the day, the worst thing that can happen to a company is you’ve got an artificial stock price that you can’t sustain,” Engel said.Competitors also spend a lot on stock promotion, he said. This “may in the short term be helping their stock price, but I’m not sure that’s sustainable without ongoing spending,” he said.The problems at CannTrust and Canopy signal a shakeout in an industry that’s still maturing nine months after Canada legalized recreational pot. Organigram is lucky because it had its wake-up call early, said Engel.The company had to recall several lots of its medical pot in late 2016 and early 2017 after it was found to contain an unapproved pesticide. Engel, who was CEO of Tilray Inc. at the time, was hired after the recall to “make a major cultural shift,” he said.“As a result of that recall, we had monthly ongoing inspections by regulators, and historically the industry was always complaining or defensive about the inspections,” Engel said. “My approach was to embrace them. At the end of the day it’s a partnership, not an adversarial relationship.”In the interview, Engel shared his views of the nascent industry:Beverages and EdiblesOrganigram isn’t being coy about its desire for a partner that can help it develop cannabis-infused beverages, similar to Constellation Brands Inc.’s investment in Canopy, Tilray’s partnership with Anheuser-Busch InBev SA or Hexo Corp.’s joint venture with Molson Coors Brewing Co.Organigram has developed a rapid-onset technology that will allow its drinks to take effect within 10 to 15 minutes, similar to alcohol, and has also created a flavorless cannabis powder that can be added to any beverage.“We wanted to go to these negotiations offering as much as possible,” Engel said. Organigram is seeking a partner from the alcohol industry that can help it develop beverages infused with THC, the cannabis compound that gets you high. It’s also seeking a consumer packaged goods partner for drinks infused with CBD, a non-intoxicating substance that’s thought to have health and wellness properties.BiosyntheticsEngel hopes Organigram’s investment in Montreal-based Hyasynth Biologicals Inc. will also help it lure a partner. Hyasynth is developing large-scale biosynthetic production of cannabinoids, or the active compounds found in cannabis. This method, which uses yeast to produce the compounds in a lab, is cheaper than extracting them from plants and will help lower production costs for products like beverages, edibles and vape pens, said Engel.U.S. Market“We’re very actively looking at the CBD market in the U.S.,” where the substance is legal at the federal level as long as it’s derived from hemp with very low THC content, Engel said. Organigram doesn’t plan to grow its own hemp but is looking at a range of possibilities, including investments in existing brands, products and companies.Corporate GovernanceOrganigram has a fully independent board of directors, a rarity in the cannabis sector. The CEO sees good corporate governance as essential to a well-run pot company.“This is an industry that’s still very much moving from founders and executives being chairmen or multiple insiders on boards, and I think some of the challenges we’ve seen in the industry have been because of a lack of governance,” he said. “You have to have independent governance that has oversight and holds management accountable.”To contact the reporter on this story: Kristine Owram in Toronto at kowram@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, ;David Scanlan at dscanlan@bloomberg.net, Jacqueline ThorpeFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • OrganiGram’s Third-Quarter Earnings
    Market Realist9 days ago

    OrganiGram’s Third-Quarter Earnings

    On Monday morning, OrganiGram's third-quarter earnings came in as a bit of a let-down. Here's why.

  • 1 Top Cannabis Stock You Can Buy and Hold for the Next Decade
    Motley Fool9 days ago

    1 Top Cannabis Stock You Can Buy and Hold for the Next Decade

    This company can help you cash in on the global marijuana boom.

  • Better Marijuana Stock: Canopy Growth vs. Constellation Brands
    Motley Fool10 days ago

    Better Marijuana Stock: Canopy Growth vs. Constellation Brands

    Pure-play pot stock or its big partner? Here's which stock looks more attractive over the long run.